Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair regrowth using finasteride, biotin, folic acid, vitamin D3, and microneedling, despite initial shedding. Vitamin D3 deficiency caused hair loss and insomnia.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 30-year-old woman with a history of anemia and low vitamin D experienced hair shedding, which improved after addressing nutrient deficiencies. Despite regrowth of terminal hairs, her dermatologist recommended treatments like minoxidil and spironolactone to prevent future bald spots, but she is cautious due to family history of hormone-related cancers.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.

Dutasteride caused persistent hair shedding and no improvement for 18 months, leading to a switch back to finasteride. The user also uses oral minoxidil and plans to focus on better scalp health.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user stopped finasteride for three months to try for a baby but continued using minoxidil and micro-needling. They are concerned about hair shedding and plan to resume finasteride after the baby is born.

The user is experiencing good hair regrowth using topical minoxidil, oral finasteride, biotin, and ketoconazole shampoo. They are curious about when the regrowth will plateau.

A user is experiencing increased hair shedding after using a homemade topical finasteride mixture with stemoxydine for six weeks. They are concerned about whether the low dose could cause shedding so early.

Minoxidil initially worked but then failed. Trinov has significantly reduced shedding and shows promising results.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

A 30-year-old with diffuse thinning and a balding crown is using a treatment regimen of a 2-in-1 pill containing finasteride, minoxidil, and biotin, along with various supplements. After two weeks, no side effects have been experienced, and updates with pictures will be posted monthly.

Apply minoxidil at least 1-2 hours before bed to ensure it dries and doesn't transfer to the pillow. Foam dries faster than liquid, and using a satin beanie after drying can help prevent transfer.

The user used Kirkland brand minoxidil foam twice daily for a year and noticed initial progress, but feels they might be losing progress or experiencing shedding. They are considering starting finasteride but prefer to avoid it and are seeking hair styling advice.

A user plans to stop finasteride to improve sperm quality for conception and seeks advice on minimizing hair loss during the break, considering using topical minoxidil and medicated shampoo. Responses suggest continuing finasteride with precautions or highlight the lack of strong alternatives to finasteride and dutasteride for hair loss prevention.

Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.

The user has been using finasteride for 7 months, along with dermarolling, Nizoral shampoo, vitamins, and minoxidil spray and oral minoxidil. They experienced variable hair shedding and improvement, and are concerned about the normalcy and future of their hair condition.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

After a year of using finasteride, topical minoxidil, Nizoral shampoo, and derma stamping, the user experienced significant hair regrowth and increased hair density, despite an initial shedding phase. The user attributes the success to consistency and patience, noting that derma stamping significantly boosted regrowth speed and quality.

The user is experiencing hair shedding while using finasteride and topical minoxidil with tretinoin, keto shampoo, and dermarolling. They hope the shedding indicates future hair regrowth.

The conversation discusses hair regrowth after 100 days using 5mg Minoxidil and 0.5mg Dutasteride, focusing on changes in the temples and hairline. Users debate the effectiveness due to inconsistent photo comparisons.

A user lost hair progress due to stress, poor nutrition, and lack of medication while in prison. They are now using a mix of natural oils and micro-needling, and plan to resume RU58841, dutasteride, and minoxidil.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.